Dean A. Fennell

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 424 citations

Medicine, Oncology, Pharmacotherapy +11

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dean A. Fennell, Keith M. Kerr, Paul E. Van Schil et al. · Annals of Oncology · 2015 · 420 citations · Full text

Medicine, Oncology, Surgery +14

Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature.

Martin P. Barr, Steven G. Gray, Andreas-Claudius Hoffmann et al. · PubMed · 2020 · 273 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell, Sean Ewings, Christian H. Ottensmeier et al. · The Lancet Oncology · 2021 · 259 citations · Full text

Medicine, Oncology, Pharmacology +15

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Lee M. Krug, Hedy L. Kindler, Hilary Calvert et al. · The Lancet Oncology · 2015 · 220 citations

Medicine, Oncology, Pharmacotherapy +10